{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-049246","form_type":"8-K","ticker":"SION","cik":"0002036042","company_name":"Sionna Therapeutics, Inc.","filed_at":"2025-11-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:41.426924+00:00","generated_at":"2026-05-17T00:26:14.488567+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Sionna Q3 net loss $20.3M; starts Phase 2a trial for SION-719; cash runway into 2028","bullets":["Net loss of $20.3M in Q3 2025 versus $25.4M in Q3 2024; R&D expenses fell to $16.0M from $24.6M due to prior year license charge.","Cash and equivalents totaled $325.0M as of Sep 30, 2025, expected to fund operations into 2028.","Initiated PreciSION CF Phase 2a proof-of-concept trial for SION-719 as add-on to standard of care in cystic fibrosis; topline data expected in mid-2026.","Initiated Phase 1 trial evaluating SION-451 in proprietary dual combinations with CFTR correctors SION-2222 and SION-109; topline data mid-2026.","Appointed Caroline Stark Beer as Chief Business Officer in September 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-049246","json":"https://secwatch.observer/filing/0001628280-25-049246.json","markdown":"https://secwatch.observer/filing/0001628280-25-049246.md","text":"https://secwatch.observer/filing/0001628280-25-049246.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2036042/000162828025049246/0001628280-25-049246-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2036042/000162828025049246/sion-20251105.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:26:14.488567+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}